Asceneuron is the second spin-off company from the EPP fund. The company is focused on the discovery and development of effective small molecule therapeutics for Alzheimer’s disease and related neurodegenerative diseases such as tauopathies. Asceneuron is based in Geneva, Switzerland.
Asceneuron appoints Peter Van Vlasselaer as Chairman
Serial biotech entrepreneur joins leading small molecule tau modulation company
2018/12/06Appoints CNS specialist and establishes US presence with new office in Cambridge, MA
2018/11/20Major milestone in development of novel treatment for progressive supranuclear palsy and other tau-related dementias
Advancement of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles
Lausanne, Switzerland, December 6, 2016 - Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, today announced the appointment of J. Michael Ryan, M.D. as Chief Medical Officer. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael brings extensive drug development expertise to Asceneuron. He will be responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.
Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners.
Lausanne, Switzerland – Asceneuron SA today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) awarded it a USD 325,000 grant ...
Lausanne, Switzerland – "The Road To Tau" - Asceneuron, an MS Ventures portfolio company ...
Lausanne, Switzerland - Asceneuron SA, an emerging leader in developing novel small molecule therapeutics targeting tauopathies for Alzheimer’s and ...
